Ignite Creation Date:
2024-05-05 @ 4:54 PM
Last Modification Date:
2024-10-26 @ 9:25 AM
Study NCT ID:
NCT00337467
Status:
COMPLETED
Last Update Posted:
2010-07-19
First Post:
2006-06-14
Brief Title:
Phase IIIb Study to Evaluate the Effectiveness and Safety of AtazanavirRitonavir as Single Enhanced Protease Inhibitor Therapy in Human Immunodeficiency Virus HIV-Infected Subjects Evidencing Virologic Suppression
Sponsor:
Bristol-Myers Squibb
Organization:
Bristol-Myers Squibb
Study Overview
Official Title:
Phase IIIb Multicenter Single Arm Open-Label Pilot Study to Evaluate the Effectiveness and Safety of Maintenance With AtazanavirRitonavir as Single Enhanced Protease Inhibitor Therapy in HIV-Infected Patients Evidencing Virologic Suppression OREY Only REYataz Study
Status:
COMPLETED
Status Verified Date:
2010-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
OREY
Brief Summary:
The main purpose is to explore whether atazanavirritonavir ATVRTV single enhanced protease inhibitor therapy can maintain virologic suppression without a marked increase in virologic failure
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None